Hematologic- and oncologic-associated rheumatic syndromes
PD-1 and CTLA-4 are essential checkpoints in T cells. Antibodies that block these checkpoints augment anti-tumor immune responses and represent a powerful therapeutic paradigm. In 2020, more than 400,000 patients will be treated with checkpoint inhibitors, highlighting the drugs' emerging potential in cancer immunotherapy. Unfortunately, 30-40 percent of these patients will develop immune-related adverse events (irAEs), including autoimmunity. As such, it is important to elucidate the mechanisms of immune-tolerance breakdown, which lead to excessive inflammation in cancer patients treated with immune-checkpoint inhibitors. At this session, faculty will review the current mechanisms underlying the pathogenesis of these adverse events and suggest approaches to translate that knowledge into clinical modalities.